论文部分内容阅读
前言很久以来,脑神经外科、神经放射科、神经内科领域中,人们一直致力于进行颅内及脊髓腔内脑室系统和蛛网膜下腔即脑脊髓液腔的造影以诊断神经系统疾病。但由于没有安全的水溶性造影剂,脑脊髓液腔的造影受到了很大限制。Metrizamide(中译名甲泛影酰胺)是非离子性水溶性造影剂,神经毒性特别是诱发癫痫的作用较少,安全性极高。它首先在北欧研制成功并使用于脑脊髓液腔的造影,目前在日本也已广泛使用。Mtetriza-mide的研制成功、CT扫描(断层扫描)、超声
Foreword For a long time, in the field of neurosurgery, neuroradiology and neurology, people have been devoting themselves to the intracranial and intracavitary ventricular system and the imaging of the subarachnoid space, that is, the cerebrospinal fluid cavity to diagnose nervous system diseases. However, due to the lack of a safe, water-soluble contrast agent, the contrast of the cerebrospinal fluid cavity has been severely limited. Metrizamide is a non-ionic water-soluble contrast agent, neurotoxicity, especially the role of less induced epilepsy, high safety. It first developed in northern Europe and used in cerebrospinal fluid cavity imaging, is also currently widely used in Japan. M tetriza-mide the successful development of CT scan (tomography), ultrasound